Company

Deep where others are broad

Airfinity provides AI-powered intelligence, simulation, and forecasting to help life sciences organisations navigate uncertainty. Our insights support faster, more confident decisions. Trusted by biopharma companies, governments, and global health leaders worldwide.

Built on a predictive analytics infrastructure refined over ten years, we combine technical excellence with deep therapy area specific drug and vaccine knowledge to inform better decisions at all levels.

Origin Story

Airfinity was founded in 2015 by Sacha Carton and Rasmus Bech Hansen to systematically capture and structure the latest medical science shared at conferences - a valuable but highly fragmented data set.

Through close collaboration with medical associations, research institutions, and pharmaceutical companies, a deeper challenge became apparent: the health and pharmaceutical industry lacked integrated, real-time insight. Critical decisions were being made on siloed, retrospective data.

In response, Airfinity built its technology to help decision-makers move from hindsight to foresight, delivering predictive intelligence that changes outcomes.

This direction became deeply personal. In 2018, Founder and CEO Rasmus Bech Hansen lost his mother to cancer after a nine-year battle. The experience instilled in him, and the company, a stronger sense of purpose, and a conviction that better, real-time information can help save lives.

The COVID-19 Pandemic

When COVID-19 emerged in early 2020, Airfinity's real-time analytics platform was uniquely positioned to deliver clarity at a moment when reliable information was scarce and urgency was total.

In a concentrated effort, the company built the world's first dedicated COVID-19 health analytics and intelligence platform. It quickly became a trusted source of real-time insight for leaders and decision-makers around the world. In 2021 alone, Airfinity data was cited more than 20,000 times in global media, reaching over 100 billion views.

The platforms and capabilities built during COVID-19 now underpin Airfinity's full suite of forecasting and intelligence products.

Solving forecasting

One silver lining of the pandemic was the acceleration it forced - across modelling capability, data integration, and forecasting rigour.

Building on those learnings, Airfinity set out on a larger mission: to build the most accurate and granular medicine and vaccine demand forecasting solution available for a select number of high-impact disease areas. We believe in the value of going deep rather than broad. Every disease area has its own forecasting and data challenges.

Our short term focus is to roll it out broadly across infectious disease and help bring down the burden of preventable disease. Next, we see huge potential in applying this to a broader set of disease and global and national health challenges.

Inaccurate forecasting, in both the short and long term, remains one of the industry's main unsolved challenges. Across infectious and chronic disease alike, forecasting errors ripple through the entire value chain. Poor forecasts cause shortages, excess inventory, and missed patient demand. For large pharma companies, these failures translate into billions in lost revenue, weaker launches, and reduced competitiveness in priority markets. For public health this pose long and short term risks.

Today, the convergence of AI, expanded compute, data scale, and advanced modelling gives the life sciences industry the tools to build dramatically better forecasts one therapy area at a time, and ultimately ensure more people get the vaccines and medicines they need.